Kura Oncology - Corporate Presentation - November 2021

DEVELOPING PRECISION MEDICINES FOR THE TREATMENT OF CANCER

Corporate Presentation - November 2021

Forward-Looking Statements

This presentation contains forward-looking statements. Such statements include, but are not limited to, statements regarding our research, preclinical and clinical development activities, plans and projected timelines for tipifarnib, KO-539 and KO-2806, plans regarding regulatory filings, our expectations regarding the relative benefits of our product candidates versus competitive therapies, and our expectations regarding the therapeutic and commercial potential of our product candidates. The words "believe," "may," "should," "will," "estimate," "promise," "plan", "continue," "anticipate," "intend," "expect," "potential" and similar expressions (including the negative thereof), are intended to identify forward-looking statements. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include: our preclinical studies and clinical trials may not be successful; the U.S. Food and Drug Administration (FDA) may not agree with our interpretation of the data from clinical trials of our product candidates; we may decide, or the FDA may require us, to conduct additional clinical trials or to modify our ongoing clinical trials; we may experience delays in the commencement, enrollment, completion or analysis of clinical testing for our product candidates, or significant issues regarding the adequacy of our clinical trial designs or the execution of our clinical trials may arise, which could result in increased costs and delays, or limit our ability to obtain regulatory approval; the commencement, enrollment and completion of clinical trials and the reporting of data therefrom; the COVID-19 pandemic may disrupt our business and that of the third parties on which we depend, including delaying or otherwise disrupting our clinical trials and preclinical studies, manufacturing and supply chain, or impairing employee productivity; our product candidates may not receive regulatory approval or be successfully commercialized; unexpected adverse side effects or inadequate therapeutic efficacy of our product candidates could delay or prevent regulatory approval or commercialization; and we may not be able to obtain additional financing. Additional risks and uncertainties may emerge from time to time, and it is not possible for Kura's management to predict all risk factors and uncertainties.

All forward-looking statements contained in this presentation speak only as of the date on which they were made. Other risks and uncertainties affecting us are described more fully in our filings with the Securities and Exchange Commission. We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Investment Highlights

Targeted Advancing targeted oncology drug candidates using a precision medicine Oncology approach; fast-to-market strategy; global commercial rights

KO-539

• Novel menin inhibitor with potential to target 35% or more of AML
• Encouraging safety, tolerability and clinical activity in multiple genetically defined subgroups of AML

Proprietary Pipeline

• Continued enrollment in Phase 1b expansion cohorts

Tipifarnib

• Breakthrough Therapy* and Fast Track Designations from FDA
• Registration-directedtrial in HRAS mutant HNSCC ongoing
• First clinical site activated in Phase 1/2 study with alpelisib in HNSCC

KO-2806

• Next-generationFTI program focused on delaying onset of drug resistance in large solid tumor indications

Strong	$543.4 million in cash** provides runway into 2024
Financials
* For the treatment of patients with recurrent or metastatic HRAS mutant HNSCC with	3
variant allele frequency ≥ 20% after disease progression on platinum-based chemotherapy

** Cash, cash equivalents and short-term investments as of September 30, 2021

Kura Leadership Team and Board of Directors

Proven oncology drug development and commercialization expertise

Leadership Team

Troy Wilson, Ph.D., J.D.

President & Chief Executive Officer

Teresa Bair, J.D.

Chief Legal Officer

Stephen Dale, M.D.

Chief Medical Officer

Kirsten Flowers

Chief Commercial Officer

Kathleen Ford

Chief Operating Officer

Marc Grasso, M.D.

Chief Financial Officer & Chief Business Officer

Board of Directors

Troy Wilson, Ph.D., J.D. (Chairman)

President and CEO, Kura Oncology

Faheem Hasnain (Lead Director)

Chairman and Chief Executive Officer, Gossamer Bio

Helen Collins, M.D.

Former Chief Medical Officer, Five Prime Therapeutics

Thomas Malley

President, Mossrock Capital

Diane Parks

Former Head of U.S. Commercial, Kite Pharma

Carol Schafer

Former Vice Chair, Equity Capital Markets, Wells Fargo

Steven Stein, M.D.

Chief Medical Officer, Incyte

Mary Szela

President and CEO, TriSalus Life Sciences

4

KOMET-001: Phase 1/2 Clinical Trial of KO-539 in Patients with Relapsed or Refractory AML

Phase 1a	Phase 1b	Phase 2
Dose Escalation	Expansion Cohorts	Registration-Enabling
			Lower Dose: 200 mg
		800 mg		Evaluate genetically
					defined cohorts at RP2D
100 mg				Higher Dose: 600 mg

50 mg

OBJECTIVES

Dose escalation in all comer patients to establish MTD and/or recommended Phase 2 dose (RP2D)

• Safety and tolerability
• Pharmacokinetics
• Early evidence of anti- tumor activity

Enroll two genetically	Enroll genetically enriched
enriched cohorts to enable	cohorts at RP2D for
refinement of RP2D	registration
•	Safety and tolerability	•	Primary endpoint: CR/CRh
•	Pharmacokinetics	•	Safety and tolerability
•	Anti-tumor efficacy	•	Other secondary and
			exploratory endpoints

KOMET: Kura Oncology Menin-MLLTrial	5